Table 2 Characteristics of 67 E. coli strains in bloodstream infections among different types of leukemia based on ESBL production and resistance to Ciprofloxacin, Ceftriaxone, and Imipenem
Hematological malignancy | ESBL (n = 36) | Non-ESBL (n = 31) | Ciprofloxacin R (n = 32) | Ciprofloxacin S (n = 35) | Ceftriaxone R (n = 41) | Ceftriaxone S (n = 24) | Imipenem R (n = 4) | Imipenem S (n = 63) |
|---|---|---|---|---|---|---|---|---|
Acute myeloid leukemia | 21(58.3%) | 15(48.3%) | 15(46.8%) | 21(60%) | 18(43.9%) | 16(66.6%) | 1(25%) | 35(55.5%) |
Acute lymphatic leukemia | 8(22.2%) | 8(25.6%) | 8(25%) | 8(25%) | 12(29.2%) | 4(16.6%) | 2(50%) | 14(22.2%) |
Chronic lymphatic leukemia | 5(13.8%) | 8(25.6%) | 8(25%) | 5(14.2%) | 9(21.9%) | 0 | 0 | 12(19%) |
Chronic myeloid leukemia | 1(2.7%) | 1(3.2%) | 1(3.1%) | 1(2.8%) | 2(4.8%) | 4(16.6%) | 1(25%) | 2(3.1%) |